Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Zai Lab Limited
  6. Summary
    ZLAB   US98887Q1040

ZAI LAB LIMITED

(ZLAB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/11/2021 10/12/2021 10/13/2021 10/14/2021 10/15/2021 Date
101.7(c) 99.53(c) 102.11(c) 102.19(c) 102(c) Last
309 051 717 652 591 721 443 338 1 266 455 Volume
-0.64% -2.13% +2.59% +0.08% -0.19% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 155 M - -
Net income 2021 -511 M - -
Net cash position 2021 1 481 M - -
P/E ratio 2021 -15,7x
Yield 2021 -
Sales 2022 347 M - -
Net income 2022 -317 M - -
Net cash position 2022 667 M - -
P/E ratio 2022 -28,1x
Yield 2022 -
Capitalization 9 732 M 9 732 M -
EV / Sales 2021 53,3x
EV / Sales 2022 26,1x
Nbr of Employees 1 194
Free-Float 100,0%
More Financials
Company
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical... 
Sector
Pharmaceuticals
Calendar
10/26 | 08:30amPresentation
More about the company
Ratings of Zai Lab Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C
More Ratings
All news about ZAI LAB LIMITED
10/15INSIDER SELL : Zai Lab
MT
10/13ZAI LAB : Working With Geneseeq Technology on R&D, Commercialization of Cancer Drugs
MT
10/13Geneseeq and Zai Lab Announces Strategic Collaboration to Advance Cancer Drug R&D
CI
10/12ZAI LAB : Bernstein Starts Zai Lab at Market Perform
MT
10/11ZAI LAB : Announces Upcoming Presentations in October Investor Conferences
AQ
10/05ZAI LAB : Says HER2+ Breast Cancer Treatment Study Met Primary Safety Endpoint
MT
10/05ZAI LAB : Announces Margetuximab Achieved Primary Objective in Bridging Study in Advanced ..
GL
10/05Zai Lab Limited announces Margetuximab Achieve Primary Objective in Bridging Study in A..
CI
10/04INSIDER SELL : Zai Lab
MT
10/04ZAI LAB : Novocure in Phase 2 Trial of Gastric Cancer Combo Therapy in Greater China
MT
10/04ZAI LAB : Partner Turning Point Therapeutics Granted Breakthrough Therapy Designation for ..
AQ
10/04NOVOCURE : Zai Lab and Novocure Announce Last Patient Enrolled in Phase 2 Pilot Trial of T..
AQ
09/27Asian ADRs Move Higher in Monday Trading
MT
09/22ZAI LAB : Holds Virtual Research and Development Day
AQ
09/21Asian ADRs Rebound Tuesday
MT
More news
News in other languages on ZAI LAB LIMITED
10/13Le laboratoire Zai travaille avec Geneseeq Technology sur la R&D et la commercialisatio..
10/04VENTE D'INITIÉS : Zai Lab
10/04Zai Lab et Novocure lancent un essai de phase 2 sur la bithérapie contre le cancer gast..
09/27Les ADR asiatiques en hausse lundi
09/21Les ADR asiatiques rebondissent mardi
More news
Analyst Recommendations on ZAI LAB LIMITED
More recommendations
Chart ZAI LAB LIMITED
Duration : Period :
Zai Lab Limited Technical Analysis Chart | ZLAB | US98887Q1040 | MarketScreener
Technical analysis trends ZAI LAB LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 11
Last Close Price 102,00 $
Average target price 212,07 $
Spread / Average Target 108%
EPS Revisions
Managers and Directors
Ying Du Chairman & Chief Executive Officer
Tao Fu President, Chief Operating Officer & Director
Billy Cho Chief Financial Officer
Ning Xu Executive VP & Head-Clinical Operations
James Yan Chief Operating Officer-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
ZAI LAB LIMITED-24.63%9 732
CSL LIMITED5.08%100 638
WUXI BIOLOGICS (CAYMAN) INC.6.42%59 673
SAMSUNG BIOLOGICS CO.,LTD.5.21%48 619
BIOGEN INC.16.50%41 907
ALEXION PHARMACEUTICALS, INC.0.00%40 336